ABVC BioPharma

Capital allocation shows persistent equity issuance and significant stock‑based payments to consultants and even for rent, causing dilution.

The company recorded large non‑cash asset additions such as land and property in Taiwan and a 20% property interest in China to bolster equity, but the strategic fit and monetization paths are unclear, and certain license consideration was in private shares with uncertain fair value.

Management disclosed that certain license funds will be returned and Q3 2025 license revenue was restated to zero, reducing confidence in the licensing‑led funding model. Overall, the pattern indicates survival financing rather than high‑return reinvestment.